ISS Versus R-ISS for Risk Stratification of Multiple Myeloma Patients undergoing Autologous Stem Cell Transplant

Tamayo, Rafael Ríos

doi:10.4172/2329-6917.1000189

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition the majority of studies required a Karnofsky performance score >60% and had multiple exclusion criteria, including peripheral neuropathy >grade 2, an absence of cardiovascular disease or other significant comorbidities and no history of additional primary neoplasm (Palumbo et al , ). While the validity of R‐ISS has been reported in a small real world population of autologous stem cell transplant (ASCT) patients (Ríos‐Tamayo et al , ), ASCT in itself selects for a younger, fitter population of myeloma patients. Comorbidities are common in myeloma patients especially with the median age of myeloma diagnosis in the UK being approximately 70 years (Phekoo et al , ; Palumbo et al , ).…”

Section: Baseline Demographics Of Patients Used For Analysis Iss and mentioning

confidence: 99%

Is the revised International staging system for myeloma valid in a real world population?

et al. 2016

View full text Add to dashboard Cite

Section: Baseline Demographics Of Patients Used For Analysis Iss and mentioning

confidence: 99%

Is the revised International staging system for myeloma valid in a real world population?

et al. 2016

View full text Add to dashboard Cite

“…Several well-established or emergent prognostic factors in relation to the disease, the host, the stage and the response to therapy are involved. However, the current risk stratification systems [16][17][18][19][20] cannot accurately predict the outcome in a particular patient.…”

Section: Introductionmentioning

confidence: 99%

Epidemiology of Multiple Myeloma

Ríos-Tamayo¹,

Rodríguez²,

Chan³

et al. 2019

Update on Multiple Myeloma

View full text Add to dashboard Cite

Multiple myeloma is a heterogeneous hematological malignancy in which epidemiology plays an increasingly important role. In recent years, an unprecedented intensive research, including both clinical and molecular epidemiology, has deepened the knowledge about its pathogenesis, risk factors, and prognostic factors, leading also to the approval of new drugs. Although the etiology remains largely unknown, among the confirmed risk factors, only obesity and the exposure to certain carcinogens are potentially preventable. Familial myeloma and occupational myeloma are topics of great interest. Most population-based cancer registries show a stable incidence or only a slight trend to increase. The diagnostic delay should be avoided as much as possible. Mortality rates, including early mortality, are progressively decreasing, although infection remains the leading cause of mortality. The outcome in terms of overall survival and health-related quality of life has remarkably improved, joining the group of potentially curable malignancies. Nowadays the clinical scenario is challenging. Clinical and epidemiological variables of interest should be standardized in clinical records. Patients should be included in a population-based registry network. The clinical coordination of a multidisciplinary team in a specialized unit is needed in order to maximize the outcome of every patient.

show abstract

ISS Versus R-ISS for Risk Stratification of Multiple Myeloma Patients undergoing Autologous Stem Cell Transplant

Cited by 2 publications

References 8 publications

Is the revised International staging system for myeloma valid in a real world population?

Is the revised International staging system for myeloma valid in a real world population?

Epidemiology of Multiple Myeloma

Contact Info

Product

Resources

About